Fomivirsen

Drugs of Today

Volumn 37, Issue 4, 2001, Pages 245-255

  Grillone, L R ^a   Lanz, R ^a  

^a ISTA Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOMIVIRSEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BLINDNESS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GENE TECHNOLOGY; HUMAN; RETINITIS; REVIEW;

EID: 0034981943     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.4.620590     Document Type: Review

References (57)

1. Cytomegalovirus
2. Prevalence of cytomegalovirus infection in homosexual men
3. Cytomegalovirus infection in patients with HIV infection
4. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome
5. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
6. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy
7. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
8. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS
9. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
10. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
11. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
12. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial
13. Comparative tolerability of therapies for cytomegalovirus retinitis
14. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis
15. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro
16. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives
17. New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy
18. Basic principles of antisense therapeutics
19. The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity
20. Pharmacokinetics of antisense oligonucleotides
21. Fomivirsen sodium
22. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
23. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
24. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
25. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides
26. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs
27. Rapid nuclear accumulation of injected oligodeoxyribonucleotides
28. Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: Specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis
29. Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates
30. Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides
31. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
32. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A
33. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides
34. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320
35. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes
36. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice
37. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
38. Toxicity of oligodeoxynucleotide therapeutic agents
39. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
40. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
41. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
42. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice
43. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice
44. In vitro metabolism of phosphorothioate antisense oligonucleotides
45. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit
46. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
47. Ocular and plasma pharmacokinetics of fomivirsen sodium (Vitravene™) in AIDS patients with CMV retinitis
48. Efficacy of the antisense oligonucleotide, fomivirsen, in patients with previously untreated CMV retinitis
49. A retrospective assessment of the impact of HAART on fomivirsen (Vitravene™) efficacy for the treatment of CMV retinitis
50. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial
51. Safety profile of a new local treatment, fomivirsen (Vitravene) for CMV retinitis
52. Retinal detachment in cytomegalovirus retinitis: Intravenous vs. intravitreal therapy
53. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial
54. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS
55. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial
56. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant